Isosceles Pharmaceuticals
Robert Stein, a Duke University Graduate School alumni, has a strong background in a wide ranging expertise from drug discovery, clinical research, development, and trials in biopharmaceuticals and oncology. Robert served as Executive Director and Head of Pharmacology at Merck Sharp & Dohm, SVP of R&D and CSO for Ligand Pharmaceuticals, and EVP of Research & Pre-Clinical Development Dupont-Merck Pharmaceuticals. He also served as President of Incyte, Roche, and CEO of KineMed, Inc. as well as a Senior Advisor of R&D at Agenus, Inc. and is an Operating Partner at Samsara BioCapital.
This person is not in any offices
Isosceles Pharmaceuticals
Isosceles Pharmaceuticals is an preclinical stage biotech developing a perioperative acute pain product candidates using actives with an approved drug master file and an excellent safety profile.